Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why Cytokinetics Is Rocketing Higher Today

TheMotleyFool

0 0

Here's Why Cytokinetics Is Rocketing Higher TodayPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Shares of Cytokinetics (NASDAQ: CYTK) are up 48.4% as of 12:00 p.m. EDT on Monday. Investors were caught off guard by some encouraging results from a clinical trial with CK-274, a potential new treatment for hypertrophic cardiomyopathy (HCM).

Patients with HCM have heart muscle that becomes thicker, which can cause it to pump with too much force. Today, Cytokinetics showed us clear signs that CK-274, an oral cardiac myosin inhibitor, can safely get the hearts of HCM patients to relax.

Image source: Getty Images.

Source Fool.com

Like: 0

CYTK

Share